BETA-2 ADRENERGIC RECEPTOR

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 15:06:04 GMT 2023` Edited by `admin` on `Sat Dec 16 15:06:04 GMT 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	VZX139UJO5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BETA-2 ADRENERGIC RECEPTOR

Common Name

English

Beta-2 adrenoceptor

Common Name

English

beta2

Common Name

English

ADRB2

Common Name

English

B2AR

Common Name

English

BETA-2 ADRENORECEPTOR

Common Name

English

ADRB2R

Common Name

English

Code System Code Type Description

FDA UNII

VZX139UJO5

Created by admin on Sat Dec 16 15:06:06 GMT 2023 , Edited by admin on Sat Dec 16 15:06:06 GMT 2023

PRIMARY

UNIPROT

P07550

Created by admin on Sat Dec 16 15:06:06 GMT 2023 , Edited by admin on Sat Dec 16 15:06:06 GMT 2023

PRIMARY

From	To
1_106	1_191
1_184	1_190

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_6
N	1_15

Related Record Type Details


					9KY0QXD6LI

BITOLTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					2I4BC502BT

SALMETEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					597QB6RUS5

CGP-12177 C-11

RADIOLIGAND->TARGET

Comments:

Used for cardiac PET adrenoreceptor imaging studies

Amount:


					S384A1Y12J

ZILPATEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					FYC8314117

MELUADRINE

AGONIST -> TARGET

Amount:


					F91H02EBWT

Arformoterol

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					8MCV2NLH7Z

CGP-12388 C-11

RADIOLIGAND->TARGET

Comments:

Used for cardiac PET adrenoreceptor imaging studies

Amount:


					J7A92W69L7

DROXIDOPA

AGONIST -> TARGET

Amount:


					QF8SVZ843E

ALBUTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					22M9P70OQ9

FENOTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					N32934RHGW

SIBENADET

AGONIST -> TARGET

Amount:


					9810NUL4D1

CARMOTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					HFU99SBD7V

LAS-190792

AGONIST -> TARGET

Comments:

In spontaneous tone isolated trachea

Qualification:

EC50

Amount:


					5ZZ84GCW8B

FORMOTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					XTZ6AXU7KN

CLENBUTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					74MLR03FLC

LEVOPROPRANOLOL

INHIBITOR -> TARGET

Amount:


					EDN2NBH5SS

LEVALBUTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					A6D97U294I

SOTALOL

INHIBITOR -> TARGET

Amount:


					VD2YSN1AFD

OLODATEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					LGY1VQ9622

MILVETEROL

AGONIST -> TARGET

Amount:


					D6P84R4E5Y

Iodocyanopindolol I-125

RADIOLIGAND->TARGET

Comments:

Chinese hamster ovary (CHO) cells stably expressing the three β-adrenergic receptor subtypes at comparable levels.

Qualification:

Amount:


					5NVQ63ZG89

(-)-CGP-12177 H-3

RADIOLIGAND->TARGET

Interaction Type:

BINDING

Qualification:

Amount:


					X7I3EMM5K0

PROCATEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					7AN603V4JV

UMECLIDINIUM BROMIDE

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					L628TT009W

ISOPROTERENOL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					WP4LUA5RAK

Iodocyanopindolol

INHIBITOR -> TARGET

Comments:

Chinese hamster ovary (CHO) cells stably expressing the three β-adrenergic receptor subtypes at comparable levels.

Qualification:

Amount:


					G9L6B3W684

HEXOPRENALINE

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					9Y8NXQ24VQ

PROPRANOLOL

INHIBITOR -> TARGET

Amount:


					1IAT42T80T

BATEFENTEROL

AGONIST -> TARGET

Amount:


					53QOG569E0

METAPROTERENOL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					I0Q6O6740J

RITODRINE

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					YKH834O4BH

EPINEPHRINE

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					4EAR229231

BEDORADRINE

AGONIST -> TARGET

Amount:


					L628TT009W

ISOPROTERENOL

AGONIST -> TARGET

Amount:


					6ZE7T2VQ9F

CHF-6366

AGONIST -> TARGET

Qualification:

Amount:


					X4W3ENH1CV

NOREPINEPHRINE

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					N8ONU3L3PG

TERBUTALINE

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					5JKY92S7BR

TIMOLOL ANHYDROUS

AGONIST -> TARGET

Comments:

NON-SELECTIVE

Amount:


					46OL1UC10R

Zenidolol

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					Z7YP8B158Q

CGP-12177, (S)-

INHIBITOR -> TARGET

Interaction Type:

BINDING

Qualification:

Amount:


					OG645J8RVW

PIRBUTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					028LZY775B

VILANTEROL

AGONIST -> TARGET

Amount:


					588N0603CT

LEVISOPRENALINE

AGONIST -> TARGET

Qualification:

Amount:


					R89UMZ82MJ

CGP-12177, (±)-

INHIBITOR -> TARGET

Amount:


					F9CEF23GHV

CHF-6366 .beta.-2 metabolite

AGONIST -> TARGET

Amount:


					QXA167CM6F

ABEDITEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					Y1850G1OVC

BAMBUTEROL

AGONIST -> TARGET

Interaction Type:

SHORT-ACTING

Amount:


					YZ574930OD

SR-59230A FREE BASE

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					G6317AOI7K

LEVOBUNOLOL

ANTAGONIST->TARGET

Comments:

Levobunolol (LB) is the levo-rotatory isomer of bunolol, a potent, nonselective antagonist of beta-adrenergic receptors.

Amount:


					OG645J8RVW

PIRBUTEROL

AGONIST -> TARGET

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL
Molecular Formula	CHEMICAL